Modern drugs for obesity and metabolic syndrome treatment (Review)
The article reviews modern anti-obesity drugs to identify new trends in effective and safe risk factors reduction (diabetes, cardiovascular and musculoskeletal diseases, cancer). Some anti-obesity drugs have a high risk of adverse effects on the CNS and cardiovascular system, so they should be used...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)
2016-12-01
|
| Series: | Сеченовский вестник |
| Subjects: | |
| Online Access: | https://www.sechenovmedj.com/jour/article/view/575 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850050525829005312 |
|---|---|
| author | M. L. Maximov O. V. Dralova V. G. Kukes V. N. Chubarev V. V. Tarasov |
| author_facet | M. L. Maximov O. V. Dralova V. G. Kukes V. N. Chubarev V. V. Tarasov |
| author_sort | M. L. Maximov |
| collection | DOAJ |
| description | The article reviews modern anti-obesity drugs to identify new trends in effective and safe risk factors reduction (diabetes, cardiovascular and musculoskeletal diseases, cancer). Some anti-obesity drugs have a high risk of adverse effects on the CNS and cardiovascular system, so they should be used for a short-term therapy only. These drugs are cannabinoid receptor antagonists (Rimonabant), neuronal NE and 5-HT reuptake inhibitors (Sibutramine), neuronal NE, 5-HT, DA reuptake inhibitor (Tesofensine), 5HT2с receptors agonist (Lorcaserin) and other drugs affecting the central and peripheral mediator systems. That is why the treatment of obesity should focus on safe drugs that affected fat absorption (Orlistat), activated energy metabolism (Adipokines), methionine aminopeptidase 2 (MetAP2) inhibitors (Beloranib) etc. The combination of anti-obesity drugs with various mechanisms of action increases the effectiveness and reduces adverse effects (Contrave®, Empatic™, Qsymia etс). |
| format | Article |
| id | doaj-art-843ae8d8cea3423c8d09c08dd051707d |
| institution | DOAJ |
| issn | 2218-7332 2658-3348 |
| language | Russian |
| publishDate | 2016-12-01 |
| publisher | Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University) |
| record_format | Article |
| series | Сеченовский вестник |
| spelling | doaj-art-843ae8d8cea3423c8d09c08dd051707d2025-08-20T02:53:26ZrusFederal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)Сеченовский вестник2218-73322658-33482016-12-01046475269Modern drugs for obesity and metabolic syndrome treatment (Review)M. L. Maximov0O. V. Dralova1V. G. Kukes2V. N. Chubarev3V. V. Tarasov4I.M. Sechenov First MSMUI.M. Sechenov First MSMUI.M. Sechenov First MSMUI.M. Sechenov First MSMUI.M. Sechenov First MSMUThe article reviews modern anti-obesity drugs to identify new trends in effective and safe risk factors reduction (diabetes, cardiovascular and musculoskeletal diseases, cancer). Some anti-obesity drugs have a high risk of adverse effects on the CNS and cardiovascular system, so they should be used for a short-term therapy only. These drugs are cannabinoid receptor antagonists (Rimonabant), neuronal NE and 5-HT reuptake inhibitors (Sibutramine), neuronal NE, 5-HT, DA reuptake inhibitor (Tesofensine), 5HT2с receptors agonist (Lorcaserin) and other drugs affecting the central and peripheral mediator systems. That is why the treatment of obesity should focus on safe drugs that affected fat absorption (Orlistat), activated energy metabolism (Adipokines), methionine aminopeptidase 2 (MetAP2) inhibitors (Beloranib) etc. The combination of anti-obesity drugs with various mechanisms of action increases the effectiveness and reduces adverse effects (Contrave®, Empatic™, Qsymia etс).https://www.sechenovmedj.com/jour/article/view/575modern pharmacotherapy of obesitytesofensineorlistatlorcaserinsibutraminerimonabantbeloranibliraglutideqsymiaadipokines |
| spellingShingle | M. L. Maximov O. V. Dralova V. G. Kukes V. N. Chubarev V. V. Tarasov Modern drugs for obesity and metabolic syndrome treatment (Review) Сеченовский вестник modern pharmacotherapy of obesity tesofensine orlistat lorcaserin sibutramine rimonabant beloranib liraglutide qsymia adipokines |
| title | Modern drugs for obesity and metabolic syndrome treatment (Review) |
| title_full | Modern drugs for obesity and metabolic syndrome treatment (Review) |
| title_fullStr | Modern drugs for obesity and metabolic syndrome treatment (Review) |
| title_full_unstemmed | Modern drugs for obesity and metabolic syndrome treatment (Review) |
| title_short | Modern drugs for obesity and metabolic syndrome treatment (Review) |
| title_sort | modern drugs for obesity and metabolic syndrome treatment review |
| topic | modern pharmacotherapy of obesity tesofensine orlistat lorcaserin sibutramine rimonabant beloranib liraglutide qsymia adipokines |
| url | https://www.sechenovmedj.com/jour/article/view/575 |
| work_keys_str_mv | AT mlmaximov moderndrugsforobesityandmetabolicsyndrometreatmentreview AT ovdralova moderndrugsforobesityandmetabolicsyndrometreatmentreview AT vgkukes moderndrugsforobesityandmetabolicsyndrometreatmentreview AT vnchubarev moderndrugsforobesityandmetabolicsyndrometreatmentreview AT vvtarasov moderndrugsforobesityandmetabolicsyndrometreatmentreview |